Ocular seeks FDA nod for expanded indication of Dextenza eye treatment

This article was originally published here

The company submitted a supplemental new drug application (sNDA) with the regulator for new indication of Dextenza. The FDA is expected to complete the review for new indication

The post Ocular seeks FDA nod for expanded indication of Dextenza eye treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply